<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-124597</identifier>
<setSpec>0210-5705</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Gastrointestinal lesions and characteristics of acute gastrointestinal bleeding in acenocoumarol-treated patients</dc:title>
<dc:description xml:lang="en">In the last few years, the number of anticoagulated patients has signi&amp;#64257;cantly increased and, as a consequence, so have hemorrhagic complications due to this therapy. We analyzed gastrointestinal (GI) bleeding because it is the most frequent type of major bleeding in these patients, and we hypothesized that they would have lesions responsible for GI bleeding regardless of the intensity of anticoagulation, although excessively anticoagulated patients would have more serious hemorrhages. Objectives: To study the characteristics of anticoagulated patients with GI bleeding and the relationship between the degree of anticoagulation and a &amp;#64257;nding of causative lesions and bleeding severity. Patients and methods: We prospectively studied 96 patients, all anticoagulated with acenocoumarol and consecutively admitted to hospital between 01/01/2003 and 09/30/2005 because of acute GI bleeding. We excluded patients with severe liver disease, as well as nine patients with incomplete details. Results: The incidence of GI bleeding requiring hospitalization was 19.6 cases/100,000 inhabitants-year. In 90% of patients, we found a causative (85% of upper GI bleeding and 50% of lower GI bleeding) or potentially causative lesion, and 30% of them required endoscopic (..) (AU)</dc:description>
<dc:creator>Nantes, Óscar</dc:creator>
<dc:creator>Hermida, José</dc:creator>
<dc:creator>Zozaya, José Manuel</dc:creator>
<dc:creator>Montes, Ramón</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">En los últimos años ha aumentado el número de pacientes anticoagulados y en consecuencia las complicaciones hemorrágicas derivadas de este tratamiento. Analizamos las hemorragias digestivas (HD) por ser las más frecuentes entre las hemorragias mayores y planteamos que estos sujetos deben presentar lesiones responsables de la HD independientemente de la intensidad de la anticoagulación, si bien aquellos excesivamente anticoagulados presentarán hemorragias más graves.ObjetivosEstudiar las características de los pacientes anticoagulados con HD y la relación entre el grado de anticoagulación con el hallazgo de lesiones responsables y la gravedad de la hemorragia.Pacientes y métodosEstudiamos prospectivamente 96 pacientes con HD, anticoagulados con acenocumarol, ingresados consecutivamente entre el 1 de enero de 2003 y el 30 de septiembre de 2005. Se excluyeron aquellos con hepatopatía severa y 9 por faltar datos.ResultadosLa incidencia de HD fue de 19,6 casos/100.000 habitantes-año. El 90% de los (..) (AU)</dc:description>
<dc:source>Gastroenterol Hepatol;37(6): 334-341, jun.-jul. 2014. tab</dc:source>
<dc:identifier>ibc-124597</dc:identifier>
<dc:title xml:lang="es">Lesiones gastrointestinales y características de las hemorragias digestivas agudas en los pacientes anticoagulados con acenocumarol</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d932^s22020</dc:subject>
<dc:subject>^d6623^s22036</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d50271</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d78^s22020</dc:subject>
<dc:subject>^d29396^s22074</dc:subject>
<dc:type>article</dc:type>
<dc:date>201407</dc:date>
</metadata>
</record>
</ibecs-document>
